What is DYN's current stock price?

DYN (Dyne Therapeutics, Inc.) is currently trading at $17.37 with a market cap of $2.87B.

What sector is Dyne Therapeutics, Inc. in?

Dyne Therapeutics, Inc. (DYN) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is DYN a good stock to buy?

Analysts have a Buy consensus on DYN with a price target of $37.40. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

DYN Dyne Therapeutics, Inc.

Healthcare

$17.37+0.00%ClosedMarket Cap: $2.87B

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

3.31

P/S

0.00

EV/EBITDA

-4.84

DCF Value

$6.74

FCF Yield

-16.1%

Div Yield

0.0%

Margins & Returns

Gross Margin

0.0%

Operating Margin

0.0%

Net Margin

0.0%

ROE

-58.3%

ROA

-41.8%

ROIC

-45.6%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$0.00	$-120.9M	$—
Q4 null	$0.00	$-112.0M	$—
FY null	$0.00	$-446.2M	$—
Q3 null	$0.00	$-108.0M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$37.40

Target (Median)

$38.50

Target Range

$23.00 - $60.00

3 Strong Buy11 Buy2 Hold0 Sell0 Strong Sell

Evercore ISI GroupOutperform

2026-05-15

BernsteinMarket Perform

2026-05-13

Chardan CapitalBuy

2026-03-09

HC Wainwright & Co.Buy

2026-03-03

Morgan StanleyOverweight

2026-03-03

Trading Activity

Insider Trades

View All

Posner Brian Sdirector

BuyFri May 22

Lucera Erickofficer: Chief Financial Officer

SellThu May 14

Kerr Douglasofficer: Chief Medical Officer

SellThu May 14

Friedl-Naderer Johannaofficer: Chief Commercial Officer

SellThu May 14

Cox Johndirector, officer: CEO & President

SellThu May 14

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

1.08

Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was incorporated in 2017 and is headquartered in Waltham, Massachusetts..

Peers

TLX